The Conversation (0)
Immutep (NASDAQ:IMMP) announces the grant of patent no. 9,908,936 entitled “Antibody molecules to LAG-3 and uses thereof” by the United States Patent and Trade Mark Office. As quoted in the press release: The patent was filed as a divisional application and is directed to LAG525, a humanised form of Immutep’s IMP701 antibody that was originally …
Immutep (NASDAQ:IMMP) announces the grant of patent no. 9,908,936 entitled “Antibody molecules to LAG-3 and uses thereof” by the United States Patent and Trade Mark Office.
As quoted in the press release:
The patent was filed as a divisional application and is directed to LAG525, a humanised form of Immutep’s IMP701 antibody that was originally developed by Immutep S.A.S., now a wholly owned subsidiary of the Company. The patent is co-owned by Novartis AG and Immutep S.A.S. and will expire on 13 March 2035.
Latest News
Outlook Reports world
Featured Genetics Investing Stocks
Browse Companies
MARKETS
COMMODITIES
CURRENCIES